Navigation Links
Abviva Announces Further Patent Issuance for Technology Used in Breast Cancer Diagnostics and Therapeutics
Date:5/17/2010

SANTA BARBARA, Calif., May 17 /PRNewswire-FirstCall/ -- Abviva, Inc. (Pink Sheets: ABVV), a biomedical company engaged in the development and commercialization of breast cancer related applications of Mammastatin, announced today that the Japanese Patent Office issued two patents on the core technology that may be used for therapeutic applications and in the Company's breast cancer risk assessment test, the Mammastatin Serum Assay (MSA). The patents are the most recent of 13 international and U.S. patents to issue to the University of Michigan for breast cancer diagnostic and therapeutic uses of Mammastatin.    

"We are very pleased with this positive development," said Barrett Evans, CEO of Abviva. "Not only will these patent grants allow us to penetrate the Japanese market with proprietary technology, they further validate, along with previous patent grants covering 16 European countries, Canada, Australia, and the United States, the global patentability of the Mammastatin technology."

The MSA was initially developed at the University of Michigan Cancer Center and is licensed exclusively to Abviva by the University for scientific and commercial development as a blood test to assess women's health. In scientific correlation studies women who tested high with the MSA test showed to have lower risk of breast cancer than women who tested low. These findings align with results of the original research conducted at the University of Michigan Cancer Center that demonstrated Mammastatin was normally produced by breast epithelial cells in healthy women and was missing or reduced in transformed breast epithelial cells.

"This further solidifies the domestic and international intellectual property protection strategy we have implemented with the University of Michigan," continued Mr. Evans. "The issuance of this patent will be very important as we gain regulatory approval and market presence for the Mammastatin technology internationally. These newest patent grant notifications further expand our worldwide patent protection and marketability for MSA."

About Abviva

Abviva, Inc. is a biomedical company engaged in the innovation, development and commercialization of breast cancer related applications of Mammastatin, a growth inhibitory protein discovered at the University of Michigan Cancer Center that demonstrated anti-breast cancer properties. The discovery was developed into a simple breast cancer diagnostic blood test that demonstrated healthy women have high or normal levels of the protein and women with breast cancer have no detectable or very low levels of the protein. Abviva intends to commercialize the Mammastatin Serum Assay as a reference test through its wholly owned subsidiary laboratory under CLIA certification.  

Statements in this press release that are not strictly historical facts are "forward-looking" statements (identified by the words "believe", "estimate", "project", "expect" or similar expressions) within the meaning of the Private Securities Litigation Reform Act of 1995. These statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company's products and services in the marketplace, competitive factors, changes in the regulatory environment, and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission. The statements in this press release are made as of today, based upon information currently known to management, and the Company does not undertake any obligation to publicly update or revise any forward-looking statements.


'/>"/>
SOURCE Abviva, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
3. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
4. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
5. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
6. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
9. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
10. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
11. CNS Response Announces Fiscal Third Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... Feb. 10, 2016  IsoRay, Inc. (NYSE MKT: ISR), ... and medical radioisotope applications for the treatment of prostate, ... announced its financial results for the second quarter and ... 2015. --> --> ... of fiscal 2016, which ended December 31, 2015, a ...
(Date:2/10/2016)... ... , ... LATHAM, NEW YORK... Marktech Optoelectronics will feature their new ... San Francisco’s Moscone Center from February 16-18, 2016, and at the healthcare-focused BiOS Expo ... PIN diode standard packages feature a TO-46 metal can with active areas of 1.0mm ...
(Date:2/10/2016)... ... February 10, 2016 , ... Cenna Bioscience Inc., an emerging biopharmaceutical company focused ... announced today it has been selected to present at the Cavendish Global Health Impact ... Florida. The purpose of the Forum is to help family offices and foundations ...
(Date:2/9/2016)... ... February 08, 2016 , ... Net-Translators, an industry-leading provider of ... its revamped and improved website. In an on-going effort to further educate customers ... better communicate how the company designs and delivers thorough, high-quality results for its ...
Breaking Biology Technology:
(Date:1/13/2016)... DUBLIN , January 13, 2016 ... has announced the addition of the  ... - Estimation & Forecast (2015-2020)" ... http://www.researchandmarkets.com/research/7h6hnn/india_biometrics ) has announced the ... & Identification Market - Estimation & ...
(Date:1/11/2016)... 11, 2016  higi, the leading retail and ... locations, web and mobile, today announced it has ... existing investors. --> ... further innovate higi,s health platform – its network ... – including expanding services and programs to retail ...
(Date:1/8/2016)... January 8, 2016 NXTD ), ... WorldVentures ® , a privately held leading direct seller ... Inc. 5000 fastest-growing company announced that on December ... $2 million in Nxt-ID to develop a proprietary new ... Wocket ® , a unique smart wallet that serves ...
Breaking Biology News(10 mins):